Abstract
Inflammatory Bowel Disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic condition characterized by inflammation of the gastrointestinal tract. Pharmacological treatment plays a crucial role in managing IBD by reducing inflammation, inducing and maintaining remission, and improving quality of life. This article explores the major classes of drugs used in the treatment of IBD, including aminosalicylates, corticosteroids, immunomodulators, and biologics. It also discusses emerging therapies, challenges in treatment personalization, and future directions in pharmacological research aimed at optimizing IBD management.
All articles published in the American Journal of Pharmacy and Pharmacology are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows others to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given to the original author(s) and source, a link to the license must be provided, and any changes made must be indicated.
By submitting their work, authors agree to these licensing terms and retain copyright of their articles.